Ignite Creation Date:
2025-12-25 @ 4:26 AM
Ignite Modification Date:
2026-03-02 @ 4:54 PM
Study NCT ID:
NCT03259620
Status:
COMPLETED
Last Update Posted:
2023-09-14
First Post:
2017-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-06-18', 'type': 'ACTUAL'}}}}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ctinfo@mii.maruho.co.jp', 'phone': '+81-75-325-3255', 'title': 'Maruho Co.,Ltd. Kyoto R&D Center', 'organization': 'Clinical Development Dept.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': '18 weeks', 'eventGroups': [{'id': 'EG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%', 'otherNumAtRisk': 245, 'deathsNumAtRisk': 245, 'otherNumAffected': 23, 'seriousNumAtRisk': 245, 'deathsNumAffected': 1, 'seriousNumAffected': 3}, {'id': 'EG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel', 'otherNumAtRisk': 246, 'deathsNumAtRisk': 246, 'otherNumAffected': 14, 'seriousNumAtRisk': 246, 'deathsNumAffected': 1, 'seriousNumAffected': 3}], 'otherEvents': [{'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pharyngitis streptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cardiomyopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Breast cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Bacterial colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Multiple sclerosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 245, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 246, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '1'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation', 'denoms': [{'units': 'Participants', 'counts': [{'value': '226', 'groupId': 'OG000'}, {'value': '217', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%'}, {'id': 'OG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel'}], 'classes': [{'title': 'Achieved complete clearance of all treated warts', 'categories': [{'measurements': [{'value': '35', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}]}]}, {'title': 'Not achieved complete clearance of all treated warts', 'categories': [{'measurements': [{'value': '191', 'groupId': 'OG000'}, {'value': '190', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.2587', 'groupIds': ['OG000'], 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 18', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject', 'denoms': [{'units': 'Participants', 'counts': [{'value': '226', 'groupId': 'OG000'}, {'value': '217', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%'}, {'id': 'OG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel'}], 'classes': [{'categories': [{'measurements': [{'value': '0.210', 'spread': '0.3771', 'groupId': 'OG000'}, {'value': '0.191', 'spread': '0.3500', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 18', 'unitOfMeasure': 'Ratio of Cleared Warts', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '226', 'groupId': 'OG000'}, {'value': '217', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%'}, {'id': 'OG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel'}], 'classes': [{'title': 'Complete clearance of all treated warts', 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}]}, {'title': 'Not complete clearance of all treated warts', 'categories': [{'measurements': [{'value': '205', 'groupId': 'OG000'}, {'value': '198', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 12', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '226', 'groupId': 'OG000'}, {'value': '217', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%'}, {'id': 'OG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel'}], 'classes': [{'categories': [{'measurements': [{'value': '0.135', 'spread': '0.3112', 'groupId': 'OG000'}, {'value': '0.127', 'spread': '0.3020', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12', 'unitOfMeasure': 'ratio of cleared warts', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Wart Size for Each Subject', 'denoms': [{'units': 'Participants', 'counts': [{'value': '226', 'groupId': 'OG000'}, {'value': '217', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%'}, {'id': 'OG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.5', 'spread': '7.10', 'groupId': 'OG000'}, {'value': '-3.1', 'spread': '6.84', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 18', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel applied once daily Furosemide Topical Gel, 0.125%'}, {'id': 'FG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel applied once daily Vehicle Topical Gel'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '245'}, {'groupId': 'FG001', 'numSubjects': '246'}]}, {'type': 'Subjects Who Had 1 Wart', 'achievements': [{'groupId': 'FG000', 'numSubjects': '112'}, {'groupId': 'FG001', 'numSubjects': '118'}]}, {'type': 'Subjects Who Had 2 Warts', 'achievements': [{'groupId': 'FG000', 'numSubjects': '48'}, {'groupId': 'FG001', 'numSubjects': '40'}]}, {'type': 'Subjects Who Had 3 Warts', 'achievements': [{'groupId': 'FG000', 'numSubjects': '25'}, {'groupId': 'FG001', 'numSubjects': '31'}]}, {'type': 'Subjects Who Had 4 Warts', 'achievements': [{'groupId': 'FG000', 'numSubjects': '13'}, {'groupId': 'FG001', 'numSubjects': '18'}]}, {'type': 'Subjects Who Had 5 Warts', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '20'}]}, {'type': 'Subjects Who Had 6 Warts', 'achievements': [{'groupId': 'FG000', 'numSubjects': '27'}, {'groupId': 'FG001', 'numSubjects': '19'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '226'}, {'groupId': 'FG001', 'numSubjects': '217'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '19'}, {'groupId': 'FG001', 'numSubjects': '29'}]}]}], 'recruitmentDetails': 'Subjects must have 1 to 6 clearly identifiable common warts located on hands, feet, limbs, and/or trunk'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '245', 'groupId': 'BG000'}, {'value': '246', 'groupId': 'BG001'}, {'value': '491', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%'}, {'id': 'BG001', 'title': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '32.1', 'spread': '18.80', 'groupId': 'BG000'}, {'value': '30.2', 'spread': '17.26', 'groupId': 'BG001'}, {'value': '31.1', 'spread': '18.05', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Age, Customized', 'classes': [{'title': '>=2 to <12', 'categories': [{'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '41', 'groupId': 'BG001'}, {'value': '80', 'groupId': 'BG002'}]}]}, {'title': '>=12 to <18', 'categories': [{'measurements': [{'value': '40', 'groupId': 'BG000'}, {'value': '40', 'groupId': 'BG001'}, {'value': '80', 'groupId': 'BG002'}]}]}, {'title': '>=18 to <65', 'categories': [{'measurements': [{'value': '150', 'groupId': 'BG000'}, {'value': '157', 'groupId': 'BG001'}, {'value': '307', 'groupId': 'BG002'}]}]}, {'title': '>=65', 'categories': [{'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '24', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '138', 'groupId': 'BG000'}, {'value': '129', 'groupId': 'BG001'}, {'value': '267', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '107', 'groupId': 'BG000'}, {'value': '117', 'groupId': 'BG001'}, {'value': '224', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '47', 'groupId': 'BG000'}, {'value': '69', 'groupId': 'BG001'}, {'value': '116', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '198', 'groupId': 'BG000'}, {'value': '177', 'groupId': 'BG001'}, {'value': '375', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '219', 'groupId': 'BG000'}, {'value': '211', 'groupId': 'BG001'}, {'value': '430', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-05-23', 'size': 612402, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-05-18T03:22', 'hasProtocol': True}, {'date': '2017-10-25', 'size': 621383, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-05-18T03:23', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 491}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-10-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-08', 'completionDateStruct': {'date': '2018-11-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-08-21', 'studyFirstSubmitDate': '2017-08-22', 'resultsFirstSubmitDate': '2023-05-24', 'studyFirstSubmitQcDate': '2017-08-22', 'lastUpdatePostDateStruct': {'date': '2023-09-14', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-08-21', 'studyFirstPostDateStruct': {'date': '2017-08-23', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-09-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-08-22', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation', 'timeFrame': 'Week 18'}], 'secondaryOutcomes': [{'measure': 'The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject', 'timeFrame': 'Week 18'}, {'measure': 'Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12', 'timeFrame': 'Week 12'}, {'measure': 'The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject at Week 12', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Wart Size for Each Subject', 'timeFrame': 'Week 18'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Cutaneous Common Warts']}, 'descriptionModule': {'briefSummary': 'To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '2 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Subjects must have 1 to 6 clearly identifiable common warts located on hands, feet, limbs, and/or trunk\n\n * Each wart must measure 3 to 10 mm in their longest dimension (diameter) on the epidermal plane of the skin at the baseline visit,\n * Each wart must be present for at least 4 weeks at the baseline visit,\n * Plantar, facial, subungual, and other warts (e.g., flat, genital) are excluded from treatment (i.e., these wart types are excluded from treatment, however the subject is not excluded).\n* Male or female subjects 2 years of age or older\n* Females of childbearing potential who are using a highly effective form of birth control or females of non-childbearing potential\n* Negative in-office urine pregnancy test at Screening and Baseline\n* Subjects free of any clinically significant dermatologic disorder in the treatment area\n* Subjects free of any clinically significant systemic condition which will interfere with the study assessments or increase the risk of AEs\n* Subjects willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study\n\nExclusion Criteria:\n\n* Subjects who have used any wart treatments/therapies, prescription or over-the-counter, as follows:\n\n * Salicylic acid, cantharidin, sinecatechins (VeregenTM), simple occlusion (e.g., duct tape), and/or any other over-the-counter wart-removing products in the treatment area within 4 weeks of the Baseline Visit.\n * Cryotherapy (e.g., treatment with liquid nitrogen), carbon dioxide, electrodessication, laser, surgery, or other forms of mechanical destruction (e.g., emery boards, clippers, debriders, etc.) in the treatment area within 8 weeks of the Baseline Visit.\n * Treatment with immunotherapy (DPCP, DNCB or other), imiquimod, 5-fluorouracil, bleomycin, podophyllin or any other wart immunotherapy or treatment (e.g., Candida antigen) designed to stimulate immune response within 12 weeks of the Baseline Visit.\n* Female subjects who are pregnant, nursing/breastfeeding, or plan to become pregnant within the study period including the follow-up period.\n* Subjects who are immunocompromised.\n* Subjects who have taken, within 30 days prior to the Baseline visit, or require treatment with systemic immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) during the course of the study.\n* Subjects who require ongoing treatment with oral or injectable furosemide.\n* Subjects who have used an investigational drug/device within 30 days of the Baseline visit\n* Subjects with known sensitivities to any of the investigational product ingredients including furosemide (or other sulfonamides).\n* Subjects with clinically relevant/significant abnormal laboratory results, vital signs, ECG, and/or physical findings at Screening and/or Baseline\n* Subjects with a chronic medical condition or clinically significant abnormal physical or laboratory finding(s) that may require the use of a prohibited medication/treatment.\n* Subjects who currently abuse alcohol or drugs or who have a history of chronic alcohol or drug abuse within the past year.'}, 'identificationModule': {'nctId': 'NCT03259620', 'briefTitle': 'A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts', 'organization': {'class': 'INDUSTRY', 'fullName': 'Maruho Co., Ltd.'}, 'officialTitle': 'A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts', 'orgStudyIdInfo': {'id': 'CLS006-CO-PR-002'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'CLS006', 'description': 'Furosemide Topical Gel, 0.125%', 'interventionNames': ['Drug: CLS006']}, {'type': 'EXPERIMENTAL', 'label': 'CLS006 Vehicle', 'description': 'Vehicle Topical Gel', 'interventionNames': ['Drug: CLS006 Vehicle']}], 'interventions': [{'name': 'CLS006', 'type': 'DRUG', 'description': 'Furosemide Topical Gel', 'armGroupLabels': ['CLS006']}, {'name': 'CLS006 Vehicle', 'type': 'DRUG', 'description': 'Vehicle Topical Gel', 'armGroupLabels': ['CLS006 Vehicle']}]}, 'contactsLocationsModule': {'locations': [{'zip': '71913', 'city': 'Hot Springs', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Burke Pharmaceutical Research', 'geoPoint': {'lat': 34.5037, 'lon': -93.05518}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'country': 'United States', 'facility': 'Dermatology Specialists, Inc.', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '92121', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'West Dermatology Research Center', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'TCR Medical Corporation', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '80210', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'Colorado Medical Research Center, Inc.', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '33486', 'city': 'Boca Raton', 'state': 'Florida', 'country': 'United States', 'facility': 'Skin Care Research, Inc.', 'geoPoint': {'lat': 26.35869, 'lon': -80.0831}}, {'zip': '33134', 'city': 'Coral Gables', 'state': 'Florida', 'country': 'United States', 'facility': 'Dermatology Associates & Research', 'geoPoint': {'lat': 25.72149, 'lon': -80.26838}}, {'zip': '33144', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'International Dermatology Research, Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '34471', 'city': 'Ocala', 'state': 'Florida', 'country': 'United States', 'facility': 'Renstar Medical Research', 'geoPoint': {'lat': 29.1872, 'lon': -82.14009}}, {'zip': '32771', 'city': 'Sanford', 'state': 'Florida', 'country': 'United States', 'facility': 'International Clinical Research - US, LLC', 'geoPoint': {'lat': 28.80055, 'lon': -81.27312}}, {'zip': '30060', 'city': 'Marietta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Marietta Dermatology Clinical Research, Inc.', 'geoPoint': {'lat': 33.9526, 'lon': -84.54993}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '46256', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Dawes Fretzin Clinical Research Group, LLC', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '47150', 'city': 'New Albany', 'state': 'Indiana', 'country': 'United States', 'facility': 'DS Research', 'geoPoint': {'lat': 38.28562, 'lon': -85.82413}}, {'zip': '64114', 'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'facility': 'Center for Pharmaceutical Research, LLC', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'zip': '64506', 'city': 'Saint Joseph', 'state': 'Missouri', 'country': 'United States', 'facility': 'MediSearch Clinical Trials', 'geoPoint': {'lat': 39.76861, 'lon': -94.84663}}, {'zip': '08520', 'city': 'East Windsor', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Psoriasis Treatment Center of Central New Jersey', 'geoPoint': {'lat': 40.268, 'lon': -74.54043}}, {'zip': '07044', 'city': 'Verona', 'state': 'New Jersey', 'country': 'United States', 'facility': 'The Dermatology Group, P.C.', 'geoPoint': {'lat': 40.82982, 'lon': -74.24015}}, {'zip': '87106', 'city': 'Albuquerque', 'state': 'New Mexico', 'country': 'United States', 'facility': 'Academic Dermatology Associates', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'zip': '10155', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Skin Specialty Dermatology', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '28277', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Darst Dermatology', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '28277', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Dermatology Specialists of Charlotte', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '27612', 'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wake Research Associates, LLC', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'zip': '97210', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Dermatology And Research Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '19462', 'city': 'Plymouth Meeting', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Dermatology Associates of Plymouth Meeting', 'geoPoint': {'lat': 40.10233, 'lon': -75.27435}}, {'zip': '15241', 'city': 'Upper Saint Clair', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'PEAK Research, LLC', 'geoPoint': {'lat': 40.3359, 'lon': -80.08339}}, {'zip': '29407', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Clinical Research Center of the Carolinas', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '29644', 'city': 'Fountain Inn', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Palmetto Clinical Trial Services, LLC', 'geoPoint': {'lat': 34.68901, 'lon': -82.19567}}, {'zip': '37130', 'city': 'Murfreesboro', 'state': 'Tennessee', 'country': 'United States', 'facility': 'International Clinical Research - Tennessee LLC', 'geoPoint': {'lat': 35.84562, 'lon': -86.39027}}, {'zip': '37215', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Tennessee Clinical Research Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '76011', 'city': 'Arlington', 'state': 'Texas', 'country': 'United States', 'facility': 'Arlington Research Center, Inc.', 'geoPoint': {'lat': 32.73569, 'lon': -97.10807}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'The University of Texas Health Science Center at Houston', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78660', 'city': 'Pflugerville', 'state': 'Texas', 'country': 'United States', 'facility': 'Austin Institute for Clinical Research, Inc', 'geoPoint': {'lat': 30.43937, 'lon': -97.62}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Dermatology Clinical Research Center of San Antonio', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '23502', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Virginia Clinical Research, Inc.', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Maruho Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}